Drug Information

Drug (ID: DG01609) and It's Reported Resistant Information

Name	A-1155463
Synonyms	A-1155463; 1235034-55-5; CHEMBL3342332; A1155463; 2-[8-(1,3-Benzothiazol-2-Ylcarbamoyl)-3,4-Dihydroisoquinolin-2(1h)-Yl]-5-(3-{4-[3-(Dimethylamino)prop-1-Yn-1-Yl]-2-Fluorophenoxy}propyl)-1,3-Thiazole-4-Carboxylic Acid; 2-[8-[(2-Benzothiazolylamino)carbonyl]-3,4-dihydro-2(1H)-isoquinolinyl]-5-[3-[4-[3-(dimethylamino)-1-propyn-1-yl]-2-fluorophenoxy]propyl]-4-thiazolecarboxylic acid; A 1155463; SCHEMBL2501550; BCP18309; EX-A1060; BDBM50030754; MFCD29924714; s7800; ZINC163914635; CCG-270355; CS-5398; BS-14688; HY-19725; Q27453707; 2-(8-(benzo[d]thiazol-2-ylcarbamoyl)-3,4-dihydroisoquinolin-2(1H)-yl)-5-(3-(4-(3-(dimethylamino)prop-1-yn-1-yl)-2-fluorophenoxy)propyl)thiazole-4-carboxylic acid; 2-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1H-isoquinolin-2-yl]-5-[3-[4-[3-(dimethylamino)prop-1-ynyl]-2-fluorophenoxy]propyl]-1,3-thiazole-4-carboxylic acid; 3CQ Click to Show/Hide
Structure
Target	.	NOUNIPROTAC	[1]
Click to Show/Hide the Molecular Information and External Link(s) of This Drug
Formula	11
IsoSMILES	CN(C)CC#CC1=CC(=C(C=C1)OCCCC2=C(N=C(S2)N3CCC4=C(C3)C(=CC=C4)C(=O)NC5=NC6=CC=CC=C6S5)C(=O)O)F
InChI	InChI=1S/C35H32FN5O4S2/c1-40(2)17-6-8-22-14-15-28(26(36)20-22)45-19-7-13-30-31(33(43)44)38-35(47-30)41-18-16-23-9-5-10-24(25(23)21-41)32(42)39-34-37-27-11-3-4-12-29(27)46-34/h3-5,9-12,14-15,20H,7,13,16-19,21H2,1-2H3,(H,43,44)(H,37,39,42)
InChIKey	SOYCFODXNRVBTI-UHFFFAOYSA-N
PubChem CID	59447577

Type(s) of Resistant Mechanism of This Drug

UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Click to Show/Hide the Resistance Disease of This Class

Acute myeloid leukemia [ICD-11: 2A60]

Click to Show/Hide

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
Unusual Activation of Pro-survival Pathway (UAPP)			Click to Show/Hide
Key Molecule: Tyrosine-protein kinase JAK2 (JAK3)				[1]
Molecule Alteration	Missense mutation		p.V617F (c.1849G>T)	Molecule Info
Sensitive Disease	Acute myeloid leukemia [ICD-11: 2A60.0]			Disease Info
Experimental Note	Revealed Based on the Cell Line Data
In Vitro Model	SCLC cells	N.A.	Homo sapiens (Human)	N.A.
	NHL cells	N.A.	Homo sapiens (Human)	N.A.
In Vivo Model	SCID and SCID-bg mouse xenograft model			Mus musculus
Experiment for Molecule Alteration	Western blotting analysis
Experiment for Drug Resistance	CellTiter-Glo assay; Colony formation assay

References

Ref 1	Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapySci Transl Med. 2015 Mar 18;7(279):279ra40. doi: 10.1126/scitranslmed.aaa4642.